Evidence map›Paper›PMID 32296030›Full record

ReviewSignal transduction and targeted therapy2020

Targeting cancer stem cell pathways for cancer therapy.

Liqun Yang, Pengfei Shi, Gaichao Zhao, Jie Xu, Wen Peng, Jiayi Zhang, Guanghui Zhang, Xiaowen Wang, Zhen Dong, Fei Chen and 1 more

Open access · goldAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Signal transduction and targeted therapy, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1,068 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
1,068citing papers in PubMed, 1 pooled it
92.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1,068 citing papers in PubMed, 1 synthesis or guideline pooled it, 1,897 citations in OpenAlex.

  1. Pooled it
  2. Gut microbes · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Review
  9. Review
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Review

1,008 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Liqun Yang *State Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China.
Pengfei Shi *State Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China.
Gaichao ZhaoState Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China.
Jie XuState Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China.
Wen PengState Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China.
Jiayi ZhangState Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China.
Guanghui ZhangState Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China.
Xiaowen WangState Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China.
Zhen DongState Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China.
Fei ChenDepartment of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI, 48201, USA.
Hongjuan CuiState Key Laboratory of Silkworm Genome Biology, Southwest University, 400716, Chongqing, China. hongjuan.cui@gmail.com.
State Key Laboratory of Silkworm Genomic BiologySouthwest University · CNWayne State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Since cancer stem cells (CSCs) were first identified in leukemia in 1994, they have been considered promising therapeutic targets for cancer therapy. These cells have self-renewal capacity and differentiation potential and contribute to multiple tumor malignancies, such as recurrence, metastasis, heterogeneity, multidrug resistance, and radiation resistance. The biological activities of CSCs are regulated by several pluripotent transcription factors, such as OCT4, Sox2, Nanog, KLF4, and MYC. In addition, many intracellular signaling pathways, such as Wnt, NF-κB (nuclear factor-κB), Notch, Hedgehog, JAK-STAT (Janus kinase/signal transducers and activators of transcription), PI3K/AKT/mTOR (phosphoinositide 3-kinase/AKT/mammalian target of rapamycin), TGF (transforming growth factor)/SMAD, and PPAR (peroxisome proliferator-activated receptor), as well as extracellular factors, such as vascular niches, hypoxia, tumor-associated macrophages, cancer-associated fibroblasts, cancer-associated mesenchymal stem cells, extracellular matrix, and exosomes, have been shown to be very important regulators of CSCs. Molecules, vaccines, antibodies, and CAR-T (chimeric antigen receptor T cell) cells have been developed to specifically target CSCs, and some of these factors are already undergoing clinical trials. This review summarizes the characterization and identification of CSCs, depicts major factors and pathways that regulate CSC development, and discusses potential targeted therapy for CSCs.

Indexed as

Antineoplastic AgentsCancer-Associated FibroblastsGene Expression Regulation, NeoplasticHumansImmunotherapy, AdoptiveKruppel-Like Factor 4NeoplasmsNeoplastic Stem CellsNF-kappa BSignal TransductionTranscription FactorsTumor-Associated MacrophagesAntineoplastic AgentsKLF4 protein, humanKruppel-Like Factor 4NF-kappa BTranscription Factors

Identifiers

PMID32296030
PMCPMC7005297
OpenAlexW3004733773

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.